245 related articles for article (PubMed ID: 25034105)
1. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions.
Tamanoi F; Lu J
Enzymes; 2013; 34 Pt. B():181-200. PubMed ID: 25034105
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
[TBL] [Abstract][Full Text] [Related]
4. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
Morgan MA; Sebil T; Aydilek E; Peest D; Ganser A; Reuter CW
Br J Haematol; 2005 Sep; 130(6):912-25. PubMed ID: 16156861
[TBL] [Abstract][Full Text] [Related]
5. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Sebti SM; Hamilton AD
Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
[TBL] [Abstract][Full Text] [Related]
6. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development.
Rowinsky EK; Windle JJ; Von Hoff DD
J Clin Oncol; 1999 Nov; 17(11):3631-52. PubMed ID: 10550163
[TBL] [Abstract][Full Text] [Related]
7. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
Lerner EC; Qian Y; Hamilton AD; Sebti SM
J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
[TBL] [Abstract][Full Text] [Related]
8. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Sun J; Qian Y; Hamilton AD; Sebti SM
Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of K-Ras plasma membrane localization.
Cho KJ; van der Hoeven D; Hancock JF
Enzymes; 2013; 33 Pt A():249-65. PubMed ID: 25033808
[TBL] [Abstract][Full Text] [Related]
10. [Inhibitors of isoprenylation of ras p21].
Yoshimatsu K
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1495-502. PubMed ID: 9309147
[TBL] [Abstract][Full Text] [Related]
11. [Correlation between inhibitory effect of Manumycin on human hepatoma cancer cell HepG2 and Ras signal transduction pathway].
Zhou JM; Pan QC; Yang XP; Liu ZC; Liao DF; Fu LW; Liang YJ
Ai Zheng; 2002 Apr; 21(4):364-8. PubMed ID: 12452012
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic modulation of k-ras signaling in colorectal cancer.
Krens LL; Baas JM; Gelderblom H; Guchelaar HJ
Drug Discov Today; 2010 Jul; 15(13-14):502-16. PubMed ID: 20594936
[TBL] [Abstract][Full Text] [Related]
13. A Guanidyl-Based Bivalent Peptidomimetic Inhibits K-Ras Prenylation and Association with c-Raf.
Tsubamoto M; Le TK; Li M; Watanabe T; Matsumi C; Parvatkar P; Fujii H; Kato N; Sun J; Ohkanda J
Chemistry; 2019 Oct; 25(59):13531-13536. PubMed ID: 31393030
[TBL] [Abstract][Full Text] [Related]
14. [Inhibitors of Ras farnesylation: tomorrow's anticancer agents?].
Perrin D; Halazy S; Hill B
Bull Cancer; 1997 Jun; 84(6):635-42. PubMed ID: 9295868
[TBL] [Abstract][Full Text] [Related]
15. Using inhibitors of prenylation to block localization and transforming activity.
Berzat AC; Brady DC; Fiordalisi JJ; Cox AD
Methods Enzymol; 2006; 407():575-97. PubMed ID: 16757354
[TBL] [Abstract][Full Text] [Related]
16. Protein farnesyltransferase inhibitors.
Ayral-Kaloustian S; Salaski EJ
Curr Med Chem; 2002 May; 9(10):1003-32. PubMed ID: 12733981
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of chronically active ras: potential for treatment of human malignancies.
Blum R; Cox AD; Kloog Y
Recent Pat Anticancer Drug Discov; 2008 Jan; 3(1):31-47. PubMed ID: 18289122
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth.
Bredel M; Pollack IF; Freund JM; Hamilton AD; Sebti SM
Neurosurgery; 1998 Jul; 43(1):124-31; discussion 131-2. PubMed ID: 9657198
[TBL] [Abstract][Full Text] [Related]
19. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
[TBL] [Abstract][Full Text] [Related]
20. How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.
Brock EJ; Ji K; Reiners JJ; Mattingly RR
Mini Rev Med Chem; 2016; 16(5):358-69. PubMed ID: 26423696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
